|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2009-4-10
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM). Patients received either thalidomide 200 mg plus dexamethasone 40 mg, days 1 to 4 and 15 to 18 on even cycles and days 1 to 4 on odd cycles, during a 28-day cycle or to melphalan 0.25 mg/kg and prednisolone 2 mg/kg orally on days 1 to 4 during a 28- to 42-day cycle. Patients achieving stable disease or better were randomly assigned to maintenance therapy with either thalidomide 100 mg daily and 3 MU interferon alpha-2b thrice weekly or to 3 MU interferon alpha-2b thrice weekly only. TD resulted in a higher proportion of complete and very good remissions (26% vs 13%; P= .006) and overall responses (68% vs 50%; P= .002) compared with MP. Time to progression (21.2 vs 29.1 months; P= .2), and progression-free survival was similar (16.7 vs 20.7 months; P= .1), but overall survival was significantly shorter in the TD group (41.5 vs 49.4 months; P= .024). Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status. The study was registered at ClinicalTrials.gov as NCT00205751.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:AdamZdenekZ,
pubmed-author:DrachJohannesJ,
pubmed-author:EgyedMiklósM,
pubmed-author:GisslingerHeinzH,
pubmed-author:GreilRichardR,
pubmed-author:HajekRomanR,
pubmed-author:HinkeAxelA,
pubmed-author:KuhnIngridI,
pubmed-author:LabarBorisB,
pubmed-author:LudwigHeinzH,
pubmed-author:SpickaIvanI,
pubmed-author:TóthováElenaE,
pubmed-author:ZojerNiklasN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
9
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3435-42
|
|
pubmed:meshHeading |
pubmed-meshheading:18955563-Aged,
pubmed-meshheading:18955563-Aged, 80 and over,
pubmed-meshheading:18955563-Anti-Inflammatory Agents,
pubmed-meshheading:18955563-Antineoplastic Agents, Alkylating,
pubmed-meshheading:18955563-Dexamethasone,
pubmed-meshheading:18955563-Disease-Free Survival,
pubmed-meshheading:18955563-Drug Therapy, Combination,
pubmed-meshheading:18955563-Female,
pubmed-meshheading:18955563-Humans,
pubmed-meshheading:18955563-Immunosuppressive Agents,
pubmed-meshheading:18955563-Male,
pubmed-meshheading:18955563-Melphalan,
pubmed-meshheading:18955563-Middle Aged,
pubmed-meshheading:18955563-Multiple Myeloma,
pubmed-meshheading:18955563-Predictive Value of Tests,
pubmed-meshheading:18955563-Prednisolone,
pubmed-meshheading:18955563-Survival Rate,
pubmed-meshheading:18955563-Thalidomide,
pubmed-meshheading:18955563-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
|
|
pubmed:affiliation |
Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria. heinz.ludwig@wienkav.at
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
